Ortho Fused Rings In Acid Moiety Patents (Class 560/10)
  • Publication number: 20150093709
    Abstract: Acid generators comprising a carbocyclic aryl or heteroaromatic group substituted with at least one acetate moiety are provided. These acid generators are particularly useful as a photoresist composition component.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 2, 2015
    Inventor: Paul J. LaBEAUME
  • Publication number: 20150093708
    Abstract: Acid generators comprising a carbocyclic or heteroaromatic group substituted with at least one diester moiety are provided. These acid generators are particularly useful as a photoresist composition component.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 2, 2015
    Inventor: Paul J. LaBEAUME
  • Patent number: 8927586
    Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: January 6, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang
  • Publication number: 20150005527
    Abstract: The present invention relates to a process for the asymmetric oxidation of nucleophilic organic compounds, particularly metal-free, with peroxide compounds in the presence of a chiral Brønsted acid catalyst. In one detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral imidodiphosphate catalyst. In another detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral phosphoric acid catalyst.
    Type: Application
    Filed: January 8, 2013
    Publication date: January 1, 2015
    Applicant: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Benjamin List, Ilija Coric, Saihu Liao
  • Publication number: 20140212814
    Abstract: Provided is an actinic-ray- or radiation-sensitive resin composition, including any of compounds of general formula (1) below that when exposed to actinic rays or radiation, is decomposed to thereby generate an acid and a resin that when acted on by an acid, is decomposed to thereby increase its solubility in an alkali developer.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: FUJIFILM CORPORATION
    Inventors: Junichi ITO, Akinori SHIBUYA, Tomoki MATSUDA, Yoko TOKUGAWA, Toshiaki FUKUHARA, Naohiro TANGO, Kaoru IWATO, Masahiro YOSHIDOME, Shinichi SUGIYAMA, Shohei KATAOKA
  • Publication number: 20140206741
    Abstract: The present invention provides an N-substituted isopropyldimethyl azulene sulfonamide derivative as represented by formula (I), and preparation method and uses thereof, wherein R1 is an alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, amino, or a substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and amino. The N-substituted isopropyldimethyl azulene sulfonamide derivative can be used in treating gastric ulcer.
    Type: Application
    Filed: April 12, 2012
    Publication date: July 24, 2014
    Applicant: Sichuan Guokang Pharmaceutical Co., Ltd
    Inventors: Luyun Zhang, Fang Yang, Wanqi Shi, Ping Zhang, Ying Li, Shufan Yin
  • Patent number: 8664425
    Abstract: Fluorescent compositions having emission under long UV excitation can be utilized as security taggants in printing inks. The fluorescent compositions can be esters of 2-naphthalenesulfonamide, and can be produced as solids in crystal or powder form.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: March 4, 2014
    Assignee: Honeywell International Inc.
    Inventors: Thomas Potrawa, Michael Kessler
  • Publication number: 20140005235
    Abstract: The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein A1, A2, A3, A4, A5, A6, G1, G2, R1, R2, R3, L, Q1, Q2, R4, R5, R6, R7, Q2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, and Y9 are as defined in claim 1; or salts or N-oxides thereof.
    Type: Application
    Filed: March 19, 2012
    Publication date: January 2, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Pierre Joseph, Marcel Jung, Ottmar Franz Hueter, Peter Renold, Thomas Pitterna
  • Publication number: 20130324521
    Abstract: A medical product (1) introducible into a blood vessel (2) comprising a drug (3) for the treatment of an aneurysm and of arteriosclerotic diseases. The drug (3) is a farnesyltransferase inhibitor.
    Type: Application
    Filed: November 24, 2011
    Publication date: December 5, 2013
    Inventor: Reza Ghotbi
  • Publication number: 20130289050
    Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.
    Type: Application
    Filed: March 4, 2013
    Publication date: October 31, 2013
    Applicants: VITAE PHARMACEUTICALS, INC., BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Boehringer Ingelheim International GmbH, Vitae Pharmaceuticals, Inc.
  • Publication number: 20130252890
    Abstract: The invention relates to selective oestrogen receptor modulators (SERM) and methods of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception.
    Type: Application
    Filed: June 21, 2011
    Publication date: September 26, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Tim Wintermantel, Carsten Möller, Ulrich Bothe, Reinhard Nubbemeyer, Ludwig Zorn, Dirk Kosemund, Antonius Ter Laak, Rolf Bohlmann, Lars Wortmann, Donald Bierer
  • Publication number: 20130225605
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 22, 2013
    Publication date: August 29, 2013
    Applicant: SANOFI
    Inventor: SANOFI
  • Publication number: 20130224870
    Abstract: Solid phase fluorescent labeling reagents (SPR) are described that simultaneously capture and label analytes, and then efficiently release the labeled-analytes under mild conditions (SCaLER).
    Type: Application
    Filed: August 26, 2011
    Publication date: August 29, 2013
    Applicant: The Texas A&M University System
    Inventors: Gyula Vigh, Roy T. Estrada, III
  • Publication number: 20130190370
    Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.
    Type: Application
    Filed: July 27, 2011
    Publication date: July 25, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
  • Publication number: 20120219885
    Abstract: The invention relates to a novel non-crystallizing methacrylate and a method for the production thereof. The invention further relates to a photopolymer formulation comprising the methacrylate of the invention as well as to use of said photopolymer formulation for producing holographic media.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 30, 2012
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Thomas Fäcke, Friedrich-Karl Bruder, Marc-Stephan Weiser, Thomas Rölle, Dennis Hönel
  • Publication number: 20120208790
    Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 16, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Esther Martinborough, Tim Neubert, Tara Whitney, Danielle Lehsten, Tara Hampton, Nicole Zimmermann, Andreas P. Termin
  • Publication number: 20120142917
    Abstract: Disclosed herein is the use of HLM-008182, as well as its analogues formed via in-house synthesis, as a potent proteasome inhibitors. A new method was developed for HLM-008182 through a four-step protocol and the method was further optimized to a two step protocol. The synthesis in both protocols was regioselective with TiCl4. The reaction was highly efficient with microwave assisted heating and THF as solvent. The modification around the molecule HLM-008182 established primary SAR, indicating that the proteasome inhibition activity was a function of the 2-side chain.
    Type: Application
    Filed: September 6, 2011
    Publication date: June 7, 2012
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., UNIVERSITY OF SOUTH FLORIDA
    Inventors: Harshani Lawrence, Yiyu Ge, Said M. Sebti, Wayne Guida
  • Publication number: 20120129902
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: May 24, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Stephon Cornell SMITH, Renhua LI, Charles Howard MITCH, Tatiana Natali VETMAN
  • Patent number: 8163806
    Abstract: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: April 24, 2012
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S Bezwada
  • Publication number: 20120095048
    Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.
    Type: Application
    Filed: February 19, 2010
    Publication date: April 19, 2012
    Applicants: REGION MIDT JYLLAND, AARHUS UNIVERSITET
    Inventors: Henrik Amtoft Neubauer, Ove Kjaer Wiborg, Henrik Helligsø Jensen
  • Publication number: 20120088869
    Abstract: Organic materials which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizers at least one compound of the formula I wherein the general symbols are as defined in claim 1. The compounds of formula I are especially useful as stabilizers for protecting polymers and lubricants against oxidative, thermal or light-induced degradation and as scavengers for oxidized developer in color photographic material.
    Type: Application
    Filed: December 20, 2011
    Publication date: April 12, 2012
    Inventors: Michèle GERSTER, Peter NESVADBA
  • Publication number: 20120010284
    Abstract: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.
    Type: Application
    Filed: September 19, 2011
    Publication date: January 12, 2012
    Applicant: BEZWADA BIOMEDICAL, LLC
    Inventor: Rao S. Bezwada
  • Publication number: 20120009683
    Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.
    Type: Application
    Filed: July 29, 2011
    Publication date: January 12, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kyle Richard GEE, Vladimir MARTIN
  • Patent number: 8066906
    Abstract: A polymerizable compound represented by general formula (1): wherein A represents a ring assembly composed of at least two 6-membered rings each optionally having a substituent; X1 and X2 each represent a (meth)acryloyloxy group; and Y1 and Y2 each independently represent a single bond, an optionally branched alkylene group having 1 to 8 carbon atoms, an ether linkage, —COO—, —OCO—, a 6-membered ring optionally having a substituent, a naphthalene ring optionally having a substituent, or a combination thereof; the substituent being a hydrogen atom, a halogen atom, a nitrile group, an optionally branched alkyl group having 1 to 8 carbon atoms, an optionally branched alkoxy group having 1 to 8 carbon atoms, or an optionally branched alkenyl group having 2 to 8 carbon atoms, wherein the alkyl, alkoxy, or alkenyl group may have its —CH2— moiety replaced with a sulfur atom or an oxygen atom and may have its hydrogen atom replaced with a halogen atom or a nitrite group.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: November 29, 2011
    Assignee: Adeka Corporation
    Inventors: Masatomi Irisawa, Mineki Hasegawa
  • Publication number: 20110263674
    Abstract: Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.
    Type: Application
    Filed: July 6, 2011
    Publication date: October 27, 2011
    Inventor: S. Bruce King
  • Patent number: 8008297
    Abstract: The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: August 30, 2011
    Assignee: Ambrilia Biopharma Inc.
    Inventors: Brent Richard Stranix, Valerie Perron
  • Publication number: 20110201609
    Abstract: The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds.
    Type: Application
    Filed: June 30, 2009
    Publication date: August 18, 2011
    Applicants: H. Lee Moffitt Cancer Center & Research Institute, University of South Florida
    Inventors: Harshani Lawrence, Yiyu Ge, Said M. Sebti, Wayne Guida
  • Publication number: 20110190528
    Abstract: Fluorescent compositions having emission under long UV excitation can be utilized as security taggants in printing inks. The fluorescent compositions can be esters of 2-naphthalenesulfonamide, and can be produced as solids in crystal or powder form.
    Type: Application
    Filed: January 24, 2011
    Publication date: August 4, 2011
    Applicant: HONEYWELL INTERNATIONAL INC.
    Inventors: Thomas Potrawa, Michael Kessler
  • Publication number: 20100298561
    Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
    Type: Application
    Filed: July 30, 2010
    Publication date: November 25, 2010
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Akito YASUHARA, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
  • Publication number: 20100221749
    Abstract: The invention relates to a three-functional pseudo-peptidic reagent, to the various uses thereof, in particular for preparing bioluminescent reagents or optionally luminescent bio-conjugates, to the use of said reagents and bio-conjugates for functionalising solid substrates, and to the use of solid substrates thus functionalised in the detection of molecules of interest.
    Type: Application
    Filed: July 10, 2008
    Publication date: September 2, 2010
    Inventors: Guillaume Clave, Pierre-Yves Renard, Anthony Romieu, Herve Volland
  • Publication number: 20100032620
    Abstract: A polymerizable optically active compound of formula (1) has high helical twisting power. When added to a liquid crystal (LC) composition it achieves required helical pitch without largely impairing the physical and optical properties of the LC composition. The compound is suited to be compounded with a LC material, particularly a cholesteric LC material for making an optically anisotropic element excellent in heat resistance, solvent resistance, transparency, optical characteristics, and LC alignment fixing ability. The compound is also useful to form a LC alignment layer, a LC alignment controlling agent, a coating material, a protective film, etc. X1 and X2 each represent a (meth)acryloyloxy group; Y1 and Y2 each represent a single bond, an optionally branched C1-8 alkylene group, an ether linkage, a thioether linkage, —COO—, —OCO—, —OCO—O—, —S—CO—, —CO—S—, an optionally substituted 6-membered ring, an optionally substituted naphthalene ring, or a combination thereof.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 11, 2010
    Applicant: Adeka Corporation
    Inventors: Mineki Hasegawa, Masatomi Irisawa
  • Publication number: 20090326258
    Abstract: The present invention relates to novel processes for the preparation of substituted tetralin and substituted indane derivatives. The present invention is further directed to novel processes for the preparation of intermediates in the preparation of the substituted tetralin and substituted indane derivatives.
    Type: Application
    Filed: July 13, 2009
    Publication date: December 31, 2009
    Inventors: Fan Zhan-Plasket, Hua Zhong, Frank Villani
  • Patent number: 7538165
    Abstract: The invention provides an electrically conductive polyaniline composition comprising polyaniline which contains at least one of novolac resins selected from the group consisting of phenolsulfonic acid novolac resin and naphtholsulfonic acid novolac resin as a dopant. The electrically conductive polyaniline composition is obtained by contacting polyaniline with an aqueous solution of the novolac resin to dope the polyaniline with the novolac resin. The invention further provides an electrically conductive polyaniline film which comprises the polyaniline containing the novolac resin as a dopant. The electrically conductive polyaniline film is obtained by contacting film of polyaniline with an aqueous solution of the novolac resin to dope the polyaniline.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: May 26, 2009
    Assignee: Nitto Denko Corporation
    Inventor: Masao Abe
  • Publication number: 20090029389
    Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.
    Type: Application
    Filed: July 25, 2008
    Publication date: January 29, 2009
    Applicant: INVITROGEN CORPORATION
    Inventors: Kyle Richard Gee, Vladimir Martin
  • Publication number: 20080287442
    Abstract: 14-O—[(((C1-6)Alkoxy-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O—[(((C1-6)Mono- or dialkylamino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C1-8)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C0-5)-alkyl)-phenylsulfanyl)-acetyl]-mutilins 14-O-[((Guanidino-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C1-6)alkyl)-phenylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.
    Type: Application
    Filed: January 11, 2007
    Publication date: November 20, 2008
    Applicant: Nabriva Therapeutics Forschungs GmbH
    Inventors: Klaus Thirring, Gerd Ascher, Susanne Paukner, Werner Heilmayer, Rodger Novak
  • Patent number: 7446222
    Abstract: Compounds of formula (I) or derivatives thereof: wherein A, B, Z, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: November 4, 2008
    Assignee: Glaxo Group Limited
    Inventors: Rino Antonio Bit, Gerard Martin Paul Giblin, Adrian Hall, David Nigel Hurst, Ian Reginald Kilford, Neil Derek Miller, Tiziana Scoccitti
  • Publication number: 20080207751
    Abstract: The present invention relates to novel non steroidal anti-inflammatory compounds (NSAIDs) derivatives of sulindac, for the treatment/prevention, alone or in combination, of cancer.
    Type: Application
    Filed: June 12, 2006
    Publication date: August 28, 2008
    Applicant: Sulfidris s.r.l.
    Inventors: Anna Sparatore, Piero Del Soldato
  • Patent number: 7388008
    Abstract: The present invention provides lysine based compounds of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.
    Type: Grant
    Filed: August 2, 2004
    Date of Patent: June 17, 2008
    Assignee: Ambrilia Biopharma Inc.
    Inventors: Brent Richard Stranix, Valérie Perron
  • Patent number: 7365196
    Abstract: A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: April 29, 2008
    Assignees: Merck Sharp & Dohme Ltd., Merck Frosst Canada & Co.
    Inventors: Patrice Charles Belanger, Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Edward Giles McIver, Alan John Nadin, Joseph George Neduvelil, Mark Steven Shearman, Adrian Leonard Smith, Timothy Jason Sparey, Graeme Irvine Stevenson, Martin Richard Teall
  • Patent number: 7217831
    Abstract: An insecticide of formula 1 and the agriculturally acceptable salts thereof, wherein: R1 is selected from the group consisting of: the group OR5 wherein R5 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic; the group —NR6OH wherein R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, carbocyclic and substituted carbocyclic; the group NR7R8 wherein R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl and carbocyclic; and the group wherein R1 is linked to R2 to form a diradical bridging group; R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, carbocyclic, substituted carbocyclic, aryl, substituted aryl, acyl and substituted acyl; and A is a diradical linking group which has a molecular weight of preferably
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: May 15, 2007
    Assignee: Nufarm - Australia Limited
    Inventors: Richard Mark Sandeman, David Spencer Chandler, Ann Maree Duncan, Phillip Maxwell Hay
  • Patent number: 7199265
    Abstract: This invention relates to compounds of the formula (I) which are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor ?, to methods of preparing such compounds and to methods for using such compounds such as in the regulation of metabolism.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: April 3, 2007
    Assignee: Karo Bio AB
    Inventors: Li Yi-Lin, Johan Malm, Chris Litten, Ana Maria Garcia Collazo, Neeraj Garg
  • Patent number: 6936636
    Abstract: Compounds of the formula: where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: August 30, 2005
    Assignee: Allergan, Inc.
    Inventors: Santosh Sinha, Kwok Yin Tsang, Smita Bhat, Roshantha A. Chandraratna
  • Patent number: 6906046
    Abstract: Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-? and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: June 14, 2005
    Assignee: Celltech R & D Inc.
    Inventors: Randy W. Jackson, Ihab Darwish, Ted A. Baughman, J. Jeffry Howbert
  • Patent number: 6875895
    Abstract: Provided is a bis(diphenylvinyl)arene compound having a reactive functional group on phenyl group, represented by below formula (1), wherein, Ar is an arylene group and has one or more substituents; R1-R22 each independently represent a hydrogen atom, a halogen atom, cyano group, nitro group, etc., and at least one of R1-R20 is a halogen atom, etc. The arene compound has sufficient solubility in an organic solvent and excellent reactivity.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: April 5, 2005
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Takahiro Ueoka, Hideyuki Ikehira, Yoshiaki Tsubata
  • Patent number: 6846890
    Abstract: A novel norbornene derivative represented by a general formula (1m) shown below is provided. By conducting a ring opening polymerization of this norbornene derivative, or by performing a subsequent hydrogenation following the ring opening polymerization, a ring opening polymer or a hydrogenated product thereof with an excellent low birefringence can be obtained. [wherein, at least one of R1 to R4 is a group selected from the group consisting of groups represented by a general formula (1-1) shown below and groups represented by a general formula (1-2) shown below] [wherein, at least one of RA, RB and Z is a group represented by the formula —C(O)O—].
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: January 25, 2005
    Assignee: JSR Corporation
    Inventors: Nobuyuki Miyaki, Yoshikazu Miyamoto, Seiji Fukuhara, Toshihiro Ootsuki
  • Patent number: 6747148
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 8, 2004
    Assignees: Hoechst Marion Roussel Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6653483
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: November 25, 2003
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Patent number: 6632816
    Abstract: The present invention provides HIV aspartyl protease inhibitors of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may be, for example, iso-butyl, wherein X and Y, same or different, may be, for example, NH2 and F, and wherein R2 and R3 are as defined herein.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: October 14, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Jean-François Lavallée, Nicolas LeBerre, Valérie Perron
  • Patent number: 6603012
    Abstract: New compounds containing bicyclic fused rings, one of which being a phenyl moiety connected by an aliphatic chain to a cycloalkyl or aryl moiety, and pharmaceutically active salts thereof are useful as RAR selective retinoid agonists. Furthermore, such retinoic acid receptor agonists, particularly retinoic acid receptor &ggr; (RAR&ggr;) selective agonists, are useful for the treatment of emphysema and associated pulmonary diseases, as well as for the therapy and prophylaxis of dermatological disorders, for the therapy and prophylaxis of malignant and premalignant epithelial lesions, tumors and precancerous changes of the mucous membrane in the mouth, tongue, larynx, esophagus, bladder, cervix and colon.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: August 5, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paula Nanette Belloni, Synese Jolidon, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20030130345
    Abstract: Embodiments of the invention relate to C2-substituted indan-1-ones and to their physiologically acceptable salts and physiologically functional derivatives.
    Type: Application
    Filed: August 30, 2002
    Publication date: July 10, 2003
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel